The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas
Abstract
Objective Our purpose was to determine whether protein tyrosine phosphatase 1B is overexpressed in ovarian cancers, possibly altering the balance of intracellular tyrosine phosphorylation.Study design The expression of protein tyrosine phosphatase 1B was assayed in frozen sections from 54 human ovarian carcinomas and seven normal ovaries by immunochemical staining with monoclonal antibody AE4-2J, which is specific for protein tyrosine phosphatase 1B. The expression of protein tyrosine phosphatase 1B-specific messenger ribonucleic acid in tumors was determined by Northern analysis. The results were analyzed statistically by means of Fisher's exact test.Results Minimal staining was observed in normal ovarian epithelium. In contrast, 43 of 54 (79.6%) tumors displayed increased protein tyrosine phosphatase 1B expression, which is statistically associated with malignancy. Overexpression was associated with the expression of the p185c-erbB-2, p170EGFR, and p165mCSFR growth factor receptor protein tyrosine kinases. Protein tyrosine phosphatase 1B messenger ribonucleic acid expression was inconsistently increased in tumor cells.Conclusion Increased expression of protein tyrosine phosphatase 1B in ovarian cancers that also express protein tyrosine kinases suggests that protein tyrosine phosphatase 1B may play a role in the growth regulation of ovarian cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SHP836 binds to a "tunnel pocket" rather than the PTP domain, which stabilizes the inactive autoinhibitory conformation of SHP2 and prevents it from functioning as a phosphatase.
“The compound binds to a “tunnel pocket” rather than the PTP domain, which stabilizes the inactive autoinhibitory conformation of SHP2 and prevents it from functioning as a phosphatase.284”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [284]
In 2015, Novartis discovered a weak inhibitor of SHP2, SHP836 (IC50 = 12 μM), through high throughput screening.
“In 2015, Novartis discovered a weak inhibitor of SHP2, SHP836 (IC50 = 12 μM), through high throughput screening.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [284]
Citations
Cites
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,460
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
GROWTH FACTOR RECEPTOR TYROSINE KINASES
Yarden, Y., & Ullrich, A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002303 · Cited by 1,819
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Fiore, P. P. D., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,011
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck, A., Kamel, A., Whitaker, R. S., Kerns, B. J., Olt, G. J., Kinney, R., Soper, J. T., Dodge, R. K., Clarke‐Pearson, D. L., & Marks, P. J. (1990) · PubMed · Cited by 760
Self-citationFiore, P. P. D., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., & Aaronson, S. A. (1987) · Cell · doi:10.1016/0092-8674(87)90592-7 · Cited by 641
Frangioni, J. V., Beahm, P. H., Shifrin, V. I., Jost, C. A., & Neel, B. G. (1992) · Cell · doi:10.1016/0092-8674(92)90190-n · Cited by 596
Epidermal-Growth-Factor-Dependent Transformation by a Human EGF Receptor Proto-Oncogene
Velu, T. J., Beguinot, L., Vass, W. C., Willingham, M. C., Merlino, G. T., Pastan, I. H., & Lowy, D. R. (1987) · Science · doi:10.1126/science.3500513 · Cited by 433
Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)
Roussel, M. F., Dull, T. J., Rettenmier, C. W., Ralph, P., Ullrich, A., & Sherr, C. J. (1987) · Nature · doi:10.1038/325549a0 · Cited by 324
Protein-tyrosine phosphatases: The other side of the coin
Hunter, T. R. (1989) · Cell · doi:10.1016/0092-8674(89)90496-0 · Cited by 306
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer
Berchuck, A., Rodriguez, G. C., Kamel, A., et al. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)80044-x · Cited by 237
Self-citationA simplified method to culture human ovarian surface epithelium.
Kruk, P. A., Maines‐Bandiera, S., & Auersperg, N. (1990) · PubMed · Cited by 208
LaForgia, S., Morse, B., Levy, J. B., Barnea, G., Cannizzaro, L. A., Li, F., Nowell, P. C., Boghosian-Sell, L., Glick, J., & Weston, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5036 · Cited by 202
Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene.
Brown-Shimer, S. L., Johnson, K. A., HILL, D. E., et al. (1992) · PubMed · Cited by 143
Zhai, Y. F., Beittenmiller, H. F., Wang, B., et al. (1993) · PubMed · Cited by 105
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
Weiner, D. B., Kokai, Y., Wada, T., et al. (1989) · PubMed · Cited by 90
The role of peptide growth factors in epithelial ovarian cancer.
Berchuck, A., Olt, G. J., Everitt, L., et al. (1990) · PubMed · Cited by 80
Self-citationGreat expectations: protein tyrosine phosphatases in cell regulation
Brautigan, D. L. (1992) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(92)90007-l · Cited by 73
Tyson, F., Boyer, C., Kaufman, R. E., et al. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90300-g · Cited by 69
Hashimoto, N., & Goldstein, B. J. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91373-x · Cited by 23
Ingle (1991) · doi:10.1002/1097-0142(19910215)67:4
Flagged first, then by citations
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Metadata
- Authors
- Wiener, J. R., Hurteau, J. A., Kerns, B.-J. M., Whitaker, R. S., Conaway, M. R., Berchuck, A., & Bast, R. C.
- Affiliations
- Duke Medical Center (US)
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 1994-04
- Volume
- 170
- Issue
- 4
- Pages
- 1177-1183
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W1973077331
- Cited by
- 84
- References
- 21
- Citations by year
- 2026: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 1 · 2020: 7 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA39930, R01CA039930)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- PTP1B, ovarian carcinoma, protein overexpression, tyrosine phosphorylation, tyrosine kinase, c-erbB-2, EGFR, tumor growth control, gene expression
- MeSH terms
- Female, Humans, Immunohistochemistry, Ovarian Neoplasms, Tumor Cells, Cultured, Gene Expression Regulation, Enzymologic, Protein Tyrosine Phosphatases, Receptor Protein-Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
